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Introduction: Recognition of human leukocyte antigens (HLA) is of importance for 
hematopoietic stem cell transplantation. Any HLA-mismatches between the donor and 
recipient can cause graft rejection or other complications. In HLA-typing experiments, usage 
of HLA-known reference cells accompany with HLA-unknown samples is obligatory. Some 
international centers represent these cells with high expenses. On the other hand, transferring 
of these cells is problematic and in some instances is not practical.  In this study, we introduced 
umbilical cord-derived mesenchymal stem cells (MSCs) as reference cells for HLA 
genotyping. These cells are national and can be prepared locally. 
Materials and methods: We isolated MSCs from three umbilical cord and after their growth 
and proliferation, these cells were characterized by flow cytometry technique using antibodies 
to CD29, CD34, CD44, CD45, CD73, CD90 and CD105. HLA-typing was then carried out by 
PCR-SSP kits for HLA-A, -B and -DRB allele’s identification. 
Results: Isolated MSCs were positive for MSCs markers; CD29, CD44, CD73, CD90, and 
CD105 and negative for hematopoietic stem cell markers; CD34 and CD45. HLA alleles were 
determined. One of the samples was homologous for HLA alleles and the others were 
heterologous. 
Conclusion: We can develop a reference panel for HLA-typing by obtaining MSCs from 
available sources like umbilical cord. 
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Introduction 
Similarities in human leukocyte antigens 
(HLA) are of important requirements for 
bone marrow transplantation (1-4). 
Mismatching between the recipient and 
donor's HLA antigens can cause transplant 
rejection and graft versus host disease 
(GVHD) (2-6). Both serological and 
molecular techniques are used to find the 
best HLA match subjects (3, 4, 7). 
Molecular techniques are more precise and 
reliable than serological techniques (7-10). 
Different types of molecular techniques are 
used for HLA-typing (1, 3, 4). Control 
reference cells or DNAs with known HLA 
alleles are used in these techniques. (11-
14). There are some centers in the world 
that provide these control samples such as 
IHWG. Different types of cells are used to 
provide HLA panels, but many of these 
cells need special conditions for their 
growth and proliferation (3, 15, 16). On the 
other hand, any country and nation have 
their specific alleles so it is better to use the 
control samples with their own alleles. 
In this study we introduced mesenchymal 
stem cells (MSCs) as control cells in HLA-
typing. MSCs are one type of stem cells that 
are existed in different tissues such as, 
umbilical cord, wharton’s jelly, cord blood, 
bone marrow, dental pulp and adipose 
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tissues (17-21) .They have stem cells 
properties such as self-renewality and 
differentiation capacity(17, 20-24).Their 
morphology under microscope is spindle-
shape and adherent (17, 20). They are 
positive for CD29, CD44, CD73, CD90, 
CD105 and CD166 (18, 20, 21, 22, 25, 26) 
and negative for hematopoietic stem cell 
markers CD34 and CD45 (17, 20, 21, 25,). 
In this study we used MSCs as control cells 
in HLA-typing because: 
1) These cells don't need unique 
conditions for their growth and 
proliferation. 
2) These cells can be isolated from 
different sources such as, umbilical cord, 
Wharton’s jelly, cord blood, bone marrow, 
and adipose tissue so they are accessible. 
Materials and methods 
Isolation of MSCs: Three umbilical cords 
were obtained from Iranian cord blood cell 
bank in Iran Blood Transfusion 
Organization (IBTO). Umbilical cord 
specimens were cut in to very small pieces 
in sterile conditions and washed with PBS. 
Tissue pieces were put in 1mg/ml 
collagenase type IV solution (GIBCO, 
USA) and incubated in 37°C for 3-4 h. Then 
the solution was filtered to isolate cell 
suspension from debris. Cell suspension 
was washed with PBS and centrifuged. The 
supernatant was removed and cell pellet 
was dissolved in DMEM medium 
supplemented with 10% FBS, 1% penicillin 
and streptomycin (prepared from a stock 
solution of 100X concentration contained 
10,000 IU/mL penicillin and 10,000 ug/mL 
of streptomycin) and 1% L-gln and 
incubated in 37C  ْ  and 5% CO2 incubator. 
Characterization of MSCs: The 
morphology of MSCs was observed under 
inverted microscope. Immunophenotyping 
of MSCs was carried out with flow 
cytometry technique. 
Eight antibodies were used for the detection 
of CD markers of MSCs surface: anti 
CD29-FITC, anti CD34-PE, anti CD44-
FITC, anti CD45-FITC, anti CD73-PE, anti 
CD90-PE and anti CD105-FITC (all from 
BD Biosciences, USA).  
HLA genotyping: DNA was extracted 
from MSCs with viability more than 95 
percent. Salting out method was used for 
the extraction of DNA. The concentration 
and purity of extracted DNA was 
determined by NanoDrop 
spectrophotometer (WPA, UK). 
HLA genotyping and allele identification 
was carried out using PCR-SSP method. 
ABDR HLA typing kit (Olerup SSP HLA 
typing kit, Sweden) was used for HLA 
genotyping. PCR was carried out with 30 
ng of the genomic DNA in a total volume 
of 10 µl of the reaction mixture. Addition of 
DNA, master mix and Taq DNA 
polymerase was accomplished as the 
manufacturer's instructions. The PCR-
cycling conditions were as follows: initial 
denaturation at 94ºC for 2 min, followed by 
10 cycles of 94ºC for 10 s and 65ºC for 60 
s and another 20 cycles of 94ºC for 10 s, 
61ºC for 50 s and 72ºC for 30 s.PCR 
products were analyzed on a 1.5% agarose 
gel with GelRed™ (Olerup SSP HLA 
typing kit, Sweden). DNAs with specified 
alleles were used to control HLA typing 
results. 
Results 
Characterization of the isolated cells: An 
image for the cultured isolated cells was 
shown in Fig. 1. These cells were spindle-
shape and adherent.  On the other hand, 
flow cytometry technique demonstrated 
that the surface markers of isolated cells 
were related to MSCs. The isolated cells 
were positive for MSC markers including 
CD29, CD44, CD73, CD90, and CD105 
and negative for hematopoietic stem cell 
markers; CD34 and CD45 (Fig.2). This 
experiment confirmed the MSCs 
characterize for the adherent isolated cells. 
HLA-genotyping results: Concentrations of 
extracted DNA from three umbilical cord-
derived MSCs (UC-MSC 1, UC-MSC 2, 
and UC-MSC 3) were 48 µg/ml, 75 µg/ml 
and 57 µg/ml, respectively. The purity of 
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ratio of OD260 to OD280 and were in an 
acceptable range; 1.72, 1.97 and 1.86. After 
PCR amplification, for identifying the HLA 
alleles, electrophoresis of PCR products 
was accomplished on a 1.5% agarose gel 
(Fig 3 and table 1). Each typing plate 
included 96 wells: 24 for HLA-A, 48 for 
HLA-B, 23 for HLA-DRB and 1 for 
negative control. The interpretation of 
results was accomplished according to the 




Figure 1. The isolated cells (MSCs) were observed under inverted microscope and were spindle-shape and 
adherent (100 x). 
 
 
Table 1.  HLA Alleles in the studied umbilical cord MSCs. As it was shown, UC-MSC 1 was homologous for 
HLA Alleles and two others were heterologous.  
HLA: human leukocyte antigen, MSCs: Mesenchymal stem cells, UC-MSC: Umbilical cord- mesenchymal stem 
cell. 
 
Identified HLA alleles  
HLA-DR HLA-B HLA-A MSCs 
DRB1*14/ DRB3* B*39 A*24 UC-MSC 1  
DRB1*01, DRB1*11/DRB3* B*35, B*18 A*03, A*24 UC-MSC 2 
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Figure 2. Flow cytometry plots. Characterization of isolated cells (A) gating of the cells. (B and C) isotype control. 
Immunophenotyping results showed that the isolated cells were negative for CD45 and CD34 (D and E, 
respectively) and positive for CD29, CD44, CD73, CD90, and CD105 (F-G, respectively). These characters were 
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Figure 3. HLA-genotyping results using PCR-SSP kits for three umbilical cord MSCs after electrophoresis. Each 
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HLA typing is essential for stem cell 
transplantation (SCT) because HLA 
compatibility between donor and recipient 
is important (1, 4). Otherwise, the graft is 
rejected or GVHD is occurred (2, 3). On the 
other hand, in HLA-typing, a suitable HLA-
known control is necessary to be sure about 
the accuracy of HLA results (16). In this 
study, HLA typing was accomplished on 
MSCs derived from different tissues using 
PCR-SSP method. Since these cells were 
accessible and their growth and 
proliferation accomplished easily without 
need to unique medium so they could be 
used for preparing a reference panel for 
HLA genotyping. Different centers and 
companies such as IHWG, EBRCC-cell 
Culture laboratory and National Cancer 
Institute's Developmental Therapeutics 
Program (NCI-60) represented various cell 
lines or their related  DNA and offered them 
as reference panel for different purposes 
like HLA genotyping (16, 27, 28). 
Michael Witti developed high-resolution 
next-generation sequencing (NGS)-based 
HLA-typing for cell lines from IHWG and 
EBRCC-cell as reference set to demonstrate 
the potential of NGS in HLA-typing. They 
used some random to fill out reference 
panel (29). 
Hemmatpour used B lymphocyte cell lines 
as HLA-known controls in DNA-based 
HLA typing. (30). 
NCI-60 cell lines, first, were used as 
screening tools to develop anti-cancer 
drugs, in early 90,s (31). But in 2005 
Sharon Adams, performed a high-
resolution sequence-based HLA typing 
experience on this panel for using of these 
cells as tools in different biologic works 
(31). 
In the study of Degli-Esposti, 100 EBV-
transformed cells and more than 150 cell 
lines were typed and were introduced as a 
cell panel with defined HLA alleles (32). 
Kim developed a Korean HLA reference 
panel by HLA typing of more than 400 
individuals in East Asians, including 
Koreans (33). 
In the previous studies, various cell lines, 
virus-transformed cells or blood cells 
derived from healthy individuals were used 
to develop reference panels. But using of 
these panels was accompanied with 
difficulties such as not being national, not 
being easily accessible and being 
expensive. 
Conclusion 
HLA-typed MSCs could be prepared from 
each available MSC-containing tissue for 
example umbilical cord and used as 
reference cells in DNA-based HLA-typing 
techniques. These cells could be kept in 
liquid nitrogen and cultured periodically to 
obtain enough DNA as the base material in 
molecular studies.   
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